512 related articles for article (PubMed ID: 9622554)
1. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.
Baraldi PG; Cacciari B; Spalluto G; Bergonzoni M; Dionisotti S; Ongini E; Varani K; Borea PA
J Med Chem; 1998 Jun; 41(12):2126-33. PubMed ID: 9622554
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
Baraldi PG; Cacciari B; Spalluto G; Pineda de las Infantas y Villatoro MJ; Zocchi C; Dionisotti S; Ongini E
J Med Chem; 1996 Mar; 39(5):1164-71. PubMed ID: 8676354
[TBL] [Abstract][Full Text] [Related]
4. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationship of pyrazolo[3,4-d]pyrimidines: potent and selective adenosine A1 receptor antagonists.
Poulsen SA; Quinn RJ
J Med Chem; 1996 Oct; 39(21):4156-61. PubMed ID: 8863792
[TBL] [Abstract][Full Text] [Related]
6. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
[TBL] [Abstract][Full Text] [Related]
8. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
Dionisotti S; Ongini E; Zocchi C; Kull B; Arslan G; Fredholm BB
Br J Pharmacol; 1997 Jun; 121(3):353-60. PubMed ID: 9179373
[TBL] [Abstract][Full Text] [Related]
9. Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]-SCH 58261 binding.
Varani K; Gessi S; Dalpiaz A; Ongini E; Borea PA
Br J Pharmacol; 1997 Sep; 122(2):386-92. PubMed ID: 9313951
[TBL] [Abstract][Full Text] [Related]
10. [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
Varani K; Merighi S; Gessi S; Klotz KN; Leung E; Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Borea PA
Mol Pharmacol; 2000 May; 57(5):968-75. PubMed ID: 10779381
[TBL] [Abstract][Full Text] [Related]
11. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.
Zocchi C; Ongini E; Conti A; Monopoli A; Negretti A; Baraldi PG; Dionisotti S
J Pharmacol Exp Ther; 1996 Feb; 276(2):398-404. PubMed ID: 8632302
[TBL] [Abstract][Full Text] [Related]
12. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.
Müller CE; Geis U; Grahner B; Lanzner W; Eger K
J Med Chem; 1996 Jun; 39(13):2482-91. PubMed ID: 8691445
[TBL] [Abstract][Full Text] [Related]
13. Novel 3-aralkyl-7-(amino-substituted)-1,2,3-triazolo[4,5-d]pyrimidines with high affinity toward A1 adenosine receptors.
Betti L; Biagi G; Giannaccini G; Giorgi I; Livi O; Lucacchini A; Manera C; Scartoni V
J Med Chem; 1998 Feb; 41(5):668-73. PubMed ID: 9513594
[TBL] [Abstract][Full Text] [Related]
14. [3H]-SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes.
Varani K; Gessi S; Dionisotti S; Ongini E; Borea PA
Br J Pharmacol; 1998 Apr; 123(8):1723-31. PubMed ID: 9605581
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacology of pyrido[2,3-d]pyrimidinediones bearing polar substituents as adenosine receptor antagonists.
Bulicz J; Bertarelli DC; Baumert D; Fülle F; Müller CE; Heber D
Bioorg Med Chem; 2006 Apr; 14(8):2837-49. PubMed ID: 16377196
[TBL] [Abstract][Full Text] [Related]
16. Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists.
Baraldi PG; Saponaro G; Aghazadeh Tabrizi M; Baraldi S; Romagnoli R; Moorman AR; Varani K; Borea PA; Preti D
Bioorg Med Chem; 2012 Jan; 20(2):1046-59. PubMed ID: 22204739
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists.
Müller CE; Geis U; Hipp J; Schobert U; Frobenius W; Pawłowski M; Suzuki F; Sandoval-Ramírez J
J Med Chem; 1997 Dec; 40(26):4396-405. PubMed ID: 9435909
[TBL] [Abstract][Full Text] [Related]
18. A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives.
van Muijlwijk-Koezen JE; Timmerman H; Link R; van der Goot H; IJzerman AP
J Med Chem; 1998 Oct; 41(21):3987-93. PubMed ID: 9767636
[TBL] [Abstract][Full Text] [Related]
19. N6,5'-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor.
van Tilburg EW; von Frijtag Drabbe Künzel J; de Groote M; Vollinga RC; Lorenzen A; IJzerman AP
J Med Chem; 1999 Apr; 42(8):1393-400. PubMed ID: 10212125
[TBL] [Abstract][Full Text] [Related]
20. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
Lenzi O; Colotta V; Catarzi D; Varano F; Poli D; Filacchioni G; Varani K; Vincenzi F; Borea PA; Paoletta S; Morizzo E; Moro S
J Med Chem; 2009 Dec; 52(23):7640-52. PubMed ID: 19743865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
